For Dr Sun Loo, being part of an innovative clinical trial is a perfect fit. It furthers research into her field of interest – measurable residual disease (MRD), and the blood cancer she is passionate about – acute myeloid leukaemia (AML).
Leukaemia researcher, Professor Andrew Wei hopes that clinical trials in the future will be routinely based on a new strategy of targeting measurable residual disease (MRD), commencing patients on treatment before clinical relapse.
Professor Daniel Tenen, who has devoted his research career to searching for a cure for cancer, has found an “ideal target”. It’s a gene called SALL4.
One of the first things Lyndell Wills did after being diagnosed with a blood cancer was to plan her dream holiday to South Africa.
